CNSP

CNS Pharmaceuticals, Inc. (CNSP) - Q3 2025 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 2025. CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on developing anti-cancer drug candidates for brain and central nervous system (CNS) tumors. The company's primary assets are TPI 287 (an abeotaxane) and Berubicin (an anthracycline). The company is classified as a non-accelerated filer and a smaller reporting company.

Key Financial Metrics

Note: The company has no revenue. Operating expenses consist of General & Administrative ($1.06M Q3) and Research & Development ($2.20M Q3).

Material Changes vs. Prior Period

• Reduced Net Loss: The net loss for the nine months ended September 30, 2025, decreased by approximately $1.79 million compared to the same period in 2024. This improvement is primarily due to a decline in clinical trial costs for the Berubicin program and lower general and administrative expenses.
• Capital Raising: The company raised approximately $13.5 million in net proceeds from the sale of common stock and warrants during the first nine months of 2025, significantly increasing cash reserves from $6.46 million at year-end 2024 to $9.86 million.
• Debt Reduction: Notes payable decreased from $326,072 at December 31, 2024, to $30,793 at September 30, 2025, following principal repayments.
• Stock Splits: The company executed multiple reverse stock splits (1-for-50 in June 2024, 1-for-50 in February 2025, and 1-for-12 in July 2025) to maintain Nasdaq listing compliance. All historical data in the filing is retroactively adjusted.

Outlook, Risks, and Management Commentary

• Berubicin Trial Results: On March 25, 2025, the company released topline data for the Berubicin Phase II trial in Glioblastoma. While outcomes were clinically relevant and comparable to the standard of care (Lomustine), the trial did not demonstrate a statistically significant difference in overall survival, the primary endpoint. Management is evaluating potential paths forward with the FDA.
• TPI 287 Development: The company is preparing for a TPI 287 trial, estimated to cost between $12 million and $15 million. Management expects to initiate this trial in the second quarter of 2026.
• Liquidity and Going Concern: Management estimates current cash ($9.86M) is sufficient to fund operations into the second half of 2026, assuming a run rate of $5.5 million annually. However, the filing includes a "substantial doubt" going concern warning, noting that significant additional financing will be required for TPI 287 development and regulatory approval.
• Internal Control Weaknesses: The company disclosed that its disclosure controls and procedures were ineffective as of September 30, 2025. Material weaknesses include a lack of segregation of duties due to limited personnel and delays in receiving cost data from third-party Contract Research Organizations (CROs).
• Nasdaq Compliance: The company is currently subject to a Mandatory Panel Monitor regarding the Minimum Bid Price Requirement until March 31, 2026. Failure to maintain compliance could result in delisting.

Investor Verification Checklist

• Cash Burn Rate: Verify if the $5.5 million annual run rate estimate holds, given the need to fund the upcoming TPI 287 trial ($12M-$15M) which exceeds current cash on hand.
• Berubicin Strategy: Confirm the specific "paths forward" management is evaluating for Berubicin following the lack of statistical significance in the primary endpoint.
• Financing Plans: Review the status of the AGP ATM Sales Agreement (currently capped at $1.76 million remaining) and any plans for new equity offerings to fund the 2026 TPI 287 trial.
• Internal Controls: Monitor progress on remediation of material weaknesses in internal controls, specifically regarding segregation of duties and CRO data reporting.
• Nasdaq Status: Track the stock price to ensure it remains above the $1.00 minimum bid price to avoid delisting proceedings under the Mandatory Panel Monitor.